Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy

(E-pub Ahead of Print)

Author(s): Zhiquan Liang, Ziwen Lu, Yafei Zhang, Dongsheng Shang, Ruyan Li, Lanlan Liu, Zhicong Zhao, Peishan Zhang, Qiong Lin, Chunlai Feng, Yibang Zhang, Peng Liu, Zhigang Tu*, Hanqing Liu*.

Journal Name: Current Cancer Drug Targets

Submit Manuscript
Submit Proposal


Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, survival has improved little over the last 20 years. The management of patients with ovarian cancer also remains similar despite studies showing striking differences and heterogeneity among different subtypes. It is therefore clear that novel targeted therapeutics are urgently needed to improve clinical outcomes for ovarian cancer. To that end, several membrane receptors associated with pivotal cellular processes and often aberrantly overexpressed in ovarian cancer cells have emerged as potential targets for receptor-mediated therapeutic strategies including specific agents and multifunctional delivery systems based on ligand-receptor binding. This review focuses on the profiles and potentials of such strategies proposed for ovarian cancer treatment and imaging.

Keywords: ovarian cancer, membrane receptors, ligand-receptor binding, targeted therapy, targeting delivery systems

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568009618666181010091246
Price: $95

Article Metrics

PDF: 1